Matching articles for "opioid abuse"

In Brief: Over-the-Counter Narcan Nasal Spray

   
The Medical Letter on Drugs and Therapeutics • May 1, 2023;  (Issue 1675)
The FDA has approved the over-the-counter (OTC) sale of Narcan (Emergent), a nasal spray that delivers 4 mg of the opioid antagonist naloxone. Narcan nasal spray has been available by prescription since...
The FDA has approved the over-the-counter (OTC) sale of Narcan (Emergent), a nasal spray that delivers 4 mg of the opioid antagonist naloxone. Narcan nasal spray has been available by prescription since 2015 for emergency treatment of opioid overdose. Generic formulations of Narcan have also been approved; the manufacturers of these products will be required to switch them to OTC status and amend their labeling accordingly. Kloxxado, an 8-mg naloxone nasal spray, remains available only by prescription.
Med Lett Drugs Ther. 2023 May 1;65(1675):72 | Show Full IntroductionHide Full Introduction

Nalmefene Returns for Reversal of Opioid Overdose

   
The Medical Letter on Drugs and Therapeutics • September 5, 2022;  (Issue 1658)
The FDA has approved a generic injectable formulation of the opioid antagonist nalmefene (Purdue) for the management of known or suspected opioid overdose. Revex, the reference product, was withdrawn from...
The FDA has approved a generic injectable formulation of the opioid antagonist nalmefene (Purdue) for the management of known or suspected opioid overdose. Revex, the reference product, was withdrawn from the market in 2008 for commercial reasons.
Med Lett Drugs Ther. 2022 Sep 5;64(1658):141-2 | Show Full IntroductionHide Full Introduction

Zimhi - A Higher-Dose Injectable Naloxone for Opioid Overdose

   
The Medical Letter on Drugs and Therapeutics • April 18, 2022;  (Issue 1648)
The FDA has approved a higher-dose injectable formulation of the opioid antagonist naloxone (Zimhi – Adamis) for emergency treatment of opioid overdose. A single IM or SC injection of the new formulation...
The FDA has approved a higher-dose injectable formulation of the opioid antagonist naloxone (Zimhi – Adamis) for emergency treatment of opioid overdose. A single IM or SC injection of the new formulation delivers 5 mg of naloxone; injectable formulations that deliver 0.4 mg or 2 mg of the drug have been available for years. Naloxone is also available in intranasal formulations for the same indication (see Table 1).
Med Lett Drugs Ther. 2022 Apr 18;64(1648):61-2 | Show Full IntroductionHide Full Introduction

In Brief: Higher-Dose Naloxone Nasal Spray (Kloxxado) for Opioid Overdose

   
The Medical Letter on Drugs and Therapeutics • September 20, 2021;  (Issue 1633)
The FDA has approved a higher-dose intranasal naloxone formulation (Kloxxado – Hikma) for emergency treatment of opioid overdose. A single spray of the new formulation delivers 8 mg of naloxone; a...
The FDA has approved a higher-dose intranasal naloxone formulation (Kloxxado – Hikma) for emergency treatment of opioid overdose. A single spray of the new formulation delivers 8 mg of naloxone; a formulation that delivers 4 mg per spray (Narcan) was approved in 2015.
Med Lett Drugs Ther. 2021 Sep 20;63(1633):151-2 | Show Full IntroductionHide Full Introduction